Filter Results:
(176)
Show Results For
- All HBS Web
(176)
- People (1)
- News (50)
- Research (84)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
Show Results For
- All HBS Web
(176)
- People (1)
- News (50)
- Research (84)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
- 01 Mar 2017
- News
How Deep Brain Stimulation Could Change Medicine
communicating appropriately to maximize the therapeutic effects. The electrodes are placed inside the brain at the precise spot where the issue originates and communicate to a wireless monitor that tracks the neurotransmitter changes to... View Details
Keywords: Janelle Nanos
- 01 Dec 2020
- News
Digital Health Care: Empowering Consumers
symptoms of diseases like diabetes or congestive heart failure. Before the implantable congestive heart failure monitor, for example, we had very poor diagnostic tools to alert the need for ASAP therapy, but these sensors can now alert providers when View Details
Keywords: April White
- 25 Jul 2005
- Research & Ideas
An Organization Your Customers Understand
segmentation focuses on customer demographics: Will products be designed to appeal to wealthy, middle-market, or low-income customers? For the pharmaceutical business, segmentation is by therapeutic class: Will the firm focus on research... View Details
Keywords: by Robert Simons
- 09 Aug 2016
- First Look
August 9, 2016
drugs that have been shown to be therapeutically equivalent to an already approved original biologic drug—have only been approved in the United States since 2015. Europe has had biosimilar entry since 2006. This paper considers how... View Details
Keywords: Sean Silverthorne
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
heartburn, advertising may do more harm than good. Silk: Keep in mind that the use of DTCA by pharmaceutical companies is quite selective in that it tends to be concentrated in a relatively small number of therapeutic classes. The... View Details
Keywords: by Manda Salls
- 01 Sep 2015
- First Look
First Look -- September 1, 2015
(TDABC) is an innovative costing tool in healthcare that can be used to directly compare the true cost of competing technologies over the full care cycle. Rather than only comparing therapeutic effectiveness over a limited number of... View Details
Keywords: Sean Silverthorne
- 17 Jun 2020
- News
Toronto Copes with COVID-19 Via Webinars; Alumni Respond to Pandemic in Philippines
Alumni Relations Boris Tsimerinov (PLDA16, 2017), the discussion focused on differences between the state of the COVID-19 crisis in Canada, the US, and the rest of the world. The webinar touched upon most recent clinical and therapeutic... View Details
Keywords: Margie Kelley
- 18 Nov 2014
- First Look
First Look: November 18
the continuing battle affect management, talent, and the company's financial performance? Purchase this case: https://hbr.org/product/Turkcell/an/715009-PDF-ENG Harvard Business School Case 615-024 Pfizer's Centers for Therapeutic... View Details
Keywords: Sean Silverthorne
- 13 Jun 2005
- Research & Ideas
From Turf Wars to Learning Curves: How Hospitals Adopt New Technology
substitutable and the physician groups associated with each moved into closer competition with each other. Where turf wars do seem to have more of an impact is in how aggressively a hospital supports its initial investment in a given View Details
- 09 Feb 2016
- First Look
February 9, 2016
a proxy contest and a special shareholder meeting to vote on replacing Allergan's directors with a slate more favorable to the Valeant merger. The proposed Salix acquisition would give Allergan a new therapeutic market but would also make... View Details
Keywords: Sean Silverthorne
- 11 May 2010
- First Look
First Look: May 11
narrowing horizontal breadth from over a dozen therapeutic classes to just three. In 2005, Levin hired Deborah Dunsire from Novartis as CEO to lead Millennium's continuing transformation. Students are asked to put themselves in the shoes... View Details
Keywords: Martha Lagace
- 24 Sep 2020
- News
The Race for a Vaccine
Pisano says. But vaccines don’t really fit the same business model as high-volume therapeutic drugs; they have an even higher bar for safety and effectiveness, because unlike most other drugs they are administered to healthy populations.... View Details
- 31 Oct 2017
- First Look
New Research and Ideas, October 31, 2017
Potential of Patient-Reported Outcomes By: Rotenstein, Lisa, Robert S. Huckman, and Neil Wagle Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53372 forthcoming Clinical Pharmacology & View Details
Keywords: by Sean Silverthorne
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
drugs (chemically-synthesized, “small-molecule” drugs) face price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already approved original... View Details
Keywords: Sean Silverthorne
- 18 Apr 2019
- Research & Ideas
Open Innovation Contestants Build AI-Based Cancer Tool
significant published and implemented work in AI/algorithmic work already exists, we wanted to direct our interests to a therapeutic problem. The highly technical, image-related work of radiation oncology planning was highly suitable for... View Details
- 01 Jun 2000
- News
The Business of Biotech
information has a therapeutic use, we have to make a substantial investment - $350 to $500 million - in doing the clinical trial work. From a business standpoint, we need to protect our investment." "High, upstream knowledge should not be... View Details
Keywords: Julia Hanna
- 08 Jun 2010
- First Look
First Look: June 8
uncertainty of commercial partners' interest in the therapeutic approach, and the constrained donor-based fundraising environment. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/610074-PDF-ENG Data.gov Karim R. Lakhani, Robert... View Details
Keywords: Martha Lagace
- 26 Nov 2013
- First Look
First Look: November 26
Beshears, John, James J. Choi, David Laibson, Brigitte C. Madrian, and Gwendolyn Reynolds Abstract—Objectives: To assess whether the addition of a peer testimonial to an informational mailing increases conversion rates from brand name prescription medications to... View Details
Keywords: Sean Silverthorne
- 14 Aug 2018
- First Look
First Look at New Research and Ideas, August 14, 2018
decide how to bring Elyas on board, and ensure a robust strategy to maintain its leadership position in the region. Purchase this case: https://hbsp.harvard.edu/product/818022-PDF-ENG Harvard Business School Case 818-059 Spark Therapeutics: Pioneering Gene Therapy... View Details
Keywords: by Sean Silverthorne
- 01 Dec 2013
- News
Your Own Medicine
pharmaceutical company, developing their own drugs. His offer was simple. "Is your son on any treatment that is a direct result of what you have done?" he asked. "No," admitted Tracy. "I'm going to change that," Williams said. DART (Disease Action Research Therapy)... View Details